transparent gif

 

Ej inloggad.

Göteborgs universitets publikationer

Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice

Författare och institution:
Joachim T. Siaw (Institutionen för biomedicin, avdelningen för medicinsk kemi och cellbiologi); Haiying Wang (Institutionen för biomedicin, avdelningen för medicinsk kemi och cellbiologi); Kathrin Pfeifer (Institutionen för biomedicin, avdelningen för medicinsk kemi och cellbiologi); V. M. Rivera (-); Jikui Guan (Institutionen för biomedicin, avdelningen för medicinsk kemi och cellbiologi); Ruth H. Palmer (Institutionen för biomedicin, avdelningen för medicinsk kemi och cellbiologi); Bengt Hallberg (Institutionen för biomedicin, avdelningen för medicinsk kemi och cellbiologi)
Publicerad i:
Oncotarget, 7 ( 20 ) s. 29011-29022
ISSN:
1949-2553
Publikationstyp:
Artikel, refereegranskad vetenskaplig
Publiceringsår:
2016
Språk:
engelska
Fulltextlänk:
Sammanfattning (abstract):
Anaplastic lymphoma kinase (ALK) is a tyrosine kinase receptor which has been implicated in numerous solid and hematologic cancers. ALK mutations are reported in about 5-7% of neuroblastoma cases but the ALK-positive percentage increases significantly in the relapsed patient population. Crizotinib, the first clinically approved ALK inhibitor for the treatment of ALK-positive lung cancer has had less dramatic responses in neuroblastoma. Here we investigate the efficacy of a second-generation ALK inhibitor, brigatinib, in a neuroblastoma setting. Employing neuroblastoma cell lines, mouse xenograft and Drosophila melanogaster model systems expressing different constitutively active ALK variants, we show clear and efficient inhibition of ALK activity by brigatinib. Similar abrogation of ALK activity was observed in vitro employing a set of different constitutively active ALK variants in biochemical assays. These results suggest that brigatinib is an effective inhibitor of ALK kinase activity in ALK addicted neuroblastoma that should be considered as a potential future therapeutic option for ALK-positive neuroblastoma patients alone or in combination with other treatments.
Ämne (baseras på Högskoleverkets indelning av forskningsämnen):
MEDICIN OCH HÄLSOVETENSKAP ->
Klinisk medicin
Nyckelord:
anaplastic lymphoma kinase, neuroblastoma, brigatinib, AP26113, resistant mutations, lung-cancer, activating mutations, single-arm, open-label, crizotinib, tumors, gene, rearrangements, chemotherapy, expression
Postens nummer:
240087
Posten skapad:
2016-08-10 11:01

Visa i Endnote-format

Göteborgs universitet • Tel. 031-786 0000
© Göteborgs universitet 2007